Core Viewpoint - The company Jin Sangzi (06896) issued a profit warning, leading to a decline of over 23% in its stock price, currently trading at 3.79 HKD with a trading volume of 5.3713 million HKD [1] Financial Performance - The company anticipates a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The decline in profit is attributed to changes in industry conditions and adjustments in the company's product marketing strategy [1] Sales and Marketing Impact - The adjustments in marketing strategy have resulted in reduced purchases from customers and distributors in the first half of 2025, leading to a decline in both sales and profit for the company [1]

金嗓子公告，截至2025年6月30日的六个月，集团预期溢利将较2024年同期减少约37%。此下降主要归 因于2025年上半年行业形势的变化，以及集团营销策略的调整，导致客户经销商采购减少，进而影响了 销售额和溢利。 ...

Core Viewpoint - The company expects a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 due to changes in industry conditions and adjustments in product marketing strategies [1] Group 1 - The anticipated profit decline is primarily attributed to a shift in industry dynamics [1] - The company's adjustments in marketing strategies have led to a reduction in purchases by customers and distributors in the first half of 2025 [1] - As a result, both sales and profits for the first half of 2025 are expected to decline [1]

Core Viewpoint - The company, Jin Sang Zi (06896), anticipates a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024, primarily due to changes in industry conditions and adjustments in product marketing strategies [1] Group 1 - The expected profit decline is attributed to a reduction in purchases by customer distributors in the first half of 2025 [1] - The company's sales and profit are projected to decline as a result of the aforementioned factors [1]

Group 1 - The company expects a profit decrease of approximately 37% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The profit decline is primarily attributed to changes in industry conditions and adjustments in the company's product marketing strategy [1] - As a result of these changes, customer distributors reduced their purchases in the first half of 2025, leading to a decline in both sales and profit for the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 6896 盈利預警 - 1 - 本公司股東及有意投資者於買賣本公司股份時，務須審慎行事。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中華人民共和國，廣西 2025年8月11日 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 本公告由金嗓子控股集團有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文及香港聯合交易所有限公司 證券上市規則第13.09條而作出。 本公司董事會（「董事會」）謹此宣佈，根據初步評估本集團截至2025年6月30日止六個月之 未經審核中期綜合財務報表及董事會目前可得資料，與2024年同期比較，截至2 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 致： ...

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Group 1 - The monitoring report from the Chinese CDC indicates an upward trend in the COVID-19 positive rate in April, with southern provinces showing higher rates than northern ones [1] - In Hong Kong, the COVID-19 positive rate increased from 1.71% to 8.21% over four weeks, indicating a rising trend in the region [1] - Taiwan reported a significant increase in emergency visits related to COVID-19, with a 66% rise in cases and additional severe cases and deaths [1] Group 2 - The Chinese CDC reported an increase in the COVID-19 positive rate among flu-like cases in emergency departments, rising from 7.5% to 16.2% [2] - Among hospitalized severe acute respiratory infection cases, the COVID-19 positive rate increased from 3.3% to 6.3% during the monitoring period [2] - The new coronavirus has surpassed rhinovirus as the leading cause of emergency visits for flu-like cases in the specified three-week period [2] Group 3 - Relevant pharmaceutical companies in the Hong Kong stock market include Shandong Xinhua Pharmaceutical (00719), Jinhongzi (06896), Sanofi (01530), and Dongyangguang Changjiang Pharmaceutical (01558) [3]

Group 1 - The stock price of Jinsongzi (06896.HK) closed at 4.350 HKD on April 28, marking a 3.82% increase from the previous trading day and reaching a one-year high [1] - The net capital inflow for the day was 2.7694 million HKD, with 3.65548 million HKD flowing in and 886.09 thousand HKD flowing out [1] - Jinsongzi Holdings Group Limited is recognized as an outstanding technology enterprise in the national pharmaceutical industry, originally established as Liuzhou Candy Factory in March 1956 [1] Group 2 - The company focuses on the pharmaceutical and food health industries, with over sixty types of products including Jinsongzi throat lozenges and various traditional foods [2] - Jinsongzi throat lozenges are well-regarded for their effectiveness in relieving throat discomfort and have maintained a leading market share in their category, exporting to over twenty countries and regions [2] - The company has achieved multiple certifications, including GMP, HACCP, ISO9001:2000, and FDA, establishing itself as a trusted unit in quality and consumer satisfaction in China [2]